The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| XAIR | -80.74% | -98.09% | -54.68% | -98% |
| S&P | +17.35% | +108.64% | +15.84% | +181% |
Beyond Air, Inc. is a clinical-stage medical device and biopharmaceutical company. It engages in developing a nitric oxide generator and delivery system that uses nitric oxide generated from ambient air and delivers precise amounts of nitric oxide to the lungs for the potential treatment of respiratory and other diseases. It operates under the Beyond Air and Beyond Cancer segments. The firm developed the LungFit platform system, a generator and delivery system that produces nitric oxide from ambient air, eliminating the need for expensive and cumbersome cylinders. The company was founded in 2011 and is headquartered in Garden City, NY.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.76M | 157.7% |
| Gross Profit | $0.16M | 146.8% |
| Gross Margin | 8.86% | 57.6% |
| Market Cap | $16.17M | -34.4% |
| Market Cap / Employee | $0.27M | 0.0% |
| Employees | 61 | -43.0% |
| Net Income | -$8.08M | 38.1% |
| EBITDA | -$6.69M | 47.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $5.14M | 17.1% |
| Accounts Receivable | $0.80M | 69.3% |
| Inventory | 2.4 | 1.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $11.04M | -34.0% |
| Short Term Debt | $0.65M | -33.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -112.89% | -15.3% |
| Return On Invested Capital | -118.98% | -20.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$4.72M | 63.2% |
| Operating Free Cash Flow | -$4.53M | 55.5% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.00 | 1.51 | 1.66 | 1.63 | 65.47% |
| Price to Sales | 7.81 | 10.44 | 6.62 | 3.61 | -73.87% |
| Price to Tangible Book Value | 20.90 | 19.31 | 24.75 | 23.02 | 10.23% |
| Enterprise Value to EBITDA | -0.71 | -3.15 | -4.78 | -3.41 | 94.78% |
| Return on Equity | -206.0% | -272.0% | -241.4% | -323.3% | 42.90% |
| Total Debt | $17.70M | $10.72M | $11.69M | $11.69M | -33.98% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
